Herpes vax safe in early trials

Interim results of the trial showed the vaccine, based on new technology, was safe in 20 Brisbane patients who received three doses via intradermal injection. 

Along with the primary endpoint of safety and a positive antibody response, the study also found the vaccine generates a T cell response to eradicate the virus.